 |
Mesoblast Limited (ASX:MSB) FDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes
JAN 31, 2012 11:09 - Article Views: 436
Mesoblast Limited (ASX:MSB) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its proprietary adult stem cells for the treatment of Type 2 diabetes. |
 |
|
Corporate Strategy Key to Mesoblast Limited (ASX:MSB) Success
NOV 24, 2011 11:24 - Article Views: 980
Mesoblast Limited (ASX:MSB) Chief Executive, Professor Silviu Itescu, today provided shareholders at Mesoblast's Annual General Meeting with an overview of the company's corporate strategy and major highlights of recent achievements. |
|
 |
Mesoblast Limited (ASX:MSB) 2011 Chairman's Address and CEO's Presentation to Shareholders
NOV 24, 2011 09:48 - Article Views: 1,046
Mesoblast Limited (ASX:MSB) Chairman's Address and CEO's Presentation to Shareholders |
|
|
Positive Outcome From FDA Meeting For Type 2 Diabetes Clinical Program Using Intravenous Delivery of Mesoblast Limited (ASX:MSB) Proprietary Adult Stem Cells
NOV 22, 2011 10:08 - Article Views: 1,126
Global regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that it has reached agreement with the United States Food and Drug Administration (FDA) on the key elements of the company's first clinical trial using intravenous delivery of its proprietary allogeneic, or off-the-shelf, mesenchymal precursor cell (MPC) technology in patients with Type 2 Diabetes. Based on the positive outcome of the FDA meeting held on November 18, Mesoblast will file an Investigational New Drug (IND) submission within the next 30-60 days to seek clearance for patient recruitment. |
|
 |
Mesoblast Limited (ASX:MSB) Presented Positive Results from Phase 2 Trial of Adult Stem Cell Therapy at the American Heart Association Annual Meeting
NOV 15, 2011 08:25 - Article Views: 886
Regenerative medicine company Mesoblast Limited (ASX:MSB) today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor(TM) after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months. The Phase 2 trial results in 60 patients were presented at the American Heart Association annual meeting in Orlando, Florida, by the trial's independent principal investigator Dr Emerson C. Perin, Director of Research in Cardiovascular Medicine and Medical Director, Stem Cell Center, Texas Heart Institute in Houston. |
|
 |
Mesoblast Limited (ASX:MSB) Reports Positive Results Using Intravenously Injected Adult Stem Cells for Type 2 Diabetes
NOV 10, 2011 08:27 - Article Views: 1,397
Regenerative medicine company, Mesoblast Limited (ASX:MSB), today announced that a single intravenous injection of its proprietary adult stem cells resulted in significant lowering of blood sugar levels for up to eight weeks in a controlled, randomized preclinical trial in non-human primates with Type 2 diabetes. This was accompanied by significant reductions in circulating inflammatory markers to levels associated with protection against heart attacks and death in patients with Type 2 diabetes. Results of the study were presented at the Credit Suisse Healthcare conference in Phoenix, Arizona. |
|
|
Mesoblast Limited (ASX:MSB) Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases
OCT 24, 2011 09:48 - Article Views: 1,323
Regenerative medicine company Mesoblast Limited (ASX:MSB) (PINK:MBLTY) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes - neovascular ("wet") Age-related Macular Degeneration (AMD). Wet AMD causes sudden and severe central vision loss and accounts for approximately 90 percent of all blindness in the elderly. Mesoblast is developing a stem cell therapeutic product for treating various vascular diseases of the eye, including wet AMD and diabetic macular edema (DME). |
|
 |
Mesoblast Limited (ASX:MSB) Received Licensing Executives Society 2011 Deals of Distinction(TM) Award
OCT 20, 2011 10:21 - Article Views: 1,151
Mesoblast Limited (ASX:MSB) and its strategic alliance partner Cephalon Inc. were today awarded the Licensing Executives Society (U.S.A. and Canada), Inc. 2011 Deals of Distinction(TM) Award. The award was conferred for the most compelling licensing and intellectual property-related deal in the life sciences sector. |
|
 |
Mesoblast Limited (ASX:MSB) and Lonza Group (VTX:LONN) Form Strategic Global Manufacturing Alliance
SEP 27, 2011 08:27 - Article Views: 935
Global regenerative medicine company Mesoblast Limited (ASX:MSB) and Lonza Group (VTX:LONN), a world leader in biologic manufacturing, today announced that they have entered into a strategic alliance for clinical and long-term commercial production of Mesoblast's off-the-shelf (allogeneic) adult stem cell products. |
|
|
